Treating diabetes mellitus in older and oldest old patients

Current Pharmaceutical Design

Volumn 21, Issue 13, 2015, Pages 1665-1671

  Abbatecola, A M ^a   Paolisso, G ^b   Sinclair, A J ^c  

^a INRCA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

Author keywords

Anti diabetic treatment; Comorbidities; Octogenarians; Quality of life; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; LIRAGLUTIDE; MEGLITINIDE; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; COGNITIVE DEFECT; COMORBIDITY; DIABETES MELLITUS; FALLING; GERIATRIC CARE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; VERY ELDERLY; AGE; DIABETES MELLITUS, TYPE 2;

AGE FACTORS; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 84930884560     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150130120747     Document Type: Article

References (66)

1. US census bureau international data at https: //www.census.gov/prod/2009pubs/p95-09-1.pdf
2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-24.
3. Gossain VV, Carella MJ, Rovner DR. Management of diabetes in the elderly: a clinical perspective. J Assoc Acad Minority Phys 1994; 5: 22-31.
4. Sinclair A, Morley JE, Rodriguez-Mañas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012; 13(6): 497-502.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55(6): 1577-96.
6. Volpato S, Blaum C, Resnick H, et al. Women's Health and Aging Study. Comorbidities and impairments explaining the association between diabetes and lower extremity disability: The Women's Health and Aging Study. Diabetes Care 2002; 254: 678-83.
7. Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002; 25; 10: 1749-54.
8. Abbatecola AM, Rizzo MR, Barbieri M, et al. Post-prandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 672: 235-40.
9. Sinclair AJ, Conroy SP, Bayer AJ. The impact of diabetes mellitus on physical function in older people. Diabetes Care 2008; 31: 233-5.
10. Onder G, Bonassi S, Abbatecola AM, et al. Geriatrics Working Group of the Italian Medicines Agency. High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). J Gerontol A Biol Sci Med Sci 2014; 69: 430-7.
11. Fried L et al. Untangling the concepts of disability, frailty and comorbidity: implications for improved targeting and care. J Gerontol Sci A Biol Sci Med Sci 2004; 59: 255-63.
12. Rockwood K et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005; 173: 489-95.
13. Zimmet P: Diabetes epidemiology as a trigger to diabetes research. Diabetologia 1999; 42: 499-518.
14. Colagiuri S. Are lower fasting plasma glucose levels associated with improved outcomes? UK Prospective Diabetes Study. Diabetes Care 2002; 25: 1410-17.
15. Sinclair A J, Paolisso G, Castro M, Bourdel-Marchasson I, Gadsby R, Rodriguez Mañas L., European Diabetes Working Party for Older People.European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab 2011; 37 Suppl 3: S27-38
16. Brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51(5 Suppl Guidelines): S265-80.
17. American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care 2011; 34(Suppl 1): S11-61
18. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascu lar Diseases of the European Society of Cardiology (ESC) and ofthe European Association for the Study of Diabetes (EASD).
19. Rydén L, Standl E, Bartnik M, et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28(1): 88-136
20. Bhattacharyya OK, Estey EA, Cheng AY; Canadian Diabetes Association 2008. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician 2009; 55(1): 39-43.
21. Constans T, Lecomte P. Non pharmacological treatments in elderly diabetics. Diabetes Metab 2007; 33 (suppl. 1): S79-86.
22. Fiatarone MA, O'Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330(25): 1769-75.
23. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32(1): 193-203.
24. Bailey CJ, Turner RC, Radziuk J, Bailey CJ, Wiernsperger NF, et al. Metformin and its liver targets in the treatment of type 2 diabetes. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3(2): 151-69
25. Johnson JA, Majumdar SR, Simpson SH, et al. Decreased Mortality associated with the use of Metformin compared with Sulfonylurea Monotherapy in Type 2 Diabetes. Diabetes Care 2002; 25: 2244-48.
26. Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007; 24(10): 1160-3.
27. Cayea D, Boyd C, Durso SC. Individualising therapy for older adults with diabetes mellitus. Drugs Aging 2007; 24(10): 851-63;
28. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560-72.
29. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004; 27(6): 1265-70.
30. Papa G, Fedele V, Rizzo MR, et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial. Diabetes Care 2006; 29(8): 1918-20.
31. Germino FW. Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review. Clin Ther 2011; 33(12): 1868-82.
32. van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28(1): 154-63.
33. Lee A1, Patrick P, Wishart J, Horowitz M, Morley J E., The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002; 4(5): 329-35.
34. Geroldi C, Frisoni GB, Paolisso G, et al. Insulin resistance in cognitive impairment: the InCHIANTI study. Arch Neurol 2005; 62(7): 1067-72.
35. Abbatecola AM, Paolisso G, Lamponi M, et al. Insulin resistance and executive dysfunction in older persons. J Am Geriatr Soc 2004; 52(10): 1713-8.
36. Abbatecola AM, Lattanzio F, Molinari AM, et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 2010; 33(8): 1706-11.
37. Erdmann E, Charbonnel B, Wilcox RG, et al. PROactive investigators Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007; 30(11): 2773-8.
38. Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14(5): 409-18.
39. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myo-cardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-71.
40. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298(10): 1189-95.
41. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective piogli-tAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279-89.
42. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298(10): 1180-8.
43. Kahn SE, Zinman B, Lachin JM, et al. Diabetes Outcome Progression Trial (ADOPT) Study Group Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31(5): 845-51.
44. Zinman B, Haffner SM, Herman WH, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. Clin Endocrinol Metab 2010; 95(1): 134-42.
45. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinedi-ones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180(1): 32-9.
46. Pratley RE, Gilbert M. Clinical management of elderly patients with type 2 diabetes mellitus. Postgrad Med 2012; 124(1): 133-43.
47. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696-705.
48. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30(8): 1979-87.
49. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H., Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49(11): 2564-71.
50. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29(12): 2632-7.
51. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61(1): 171-80.
52. Barzilai , et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial Curr Med Res Opin 2011; 27(5): 1049-58.
53. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007; 30(12): 3017-22.
54. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009; 11(8): 804-12.
55. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5): 1083-91.
56. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in met-formin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5): 1092-100.
57. Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging 2008; 25(11): 913-25
58. Linnebjerg H, Kothare PA, Seger M, Wolka AM, Mitchell MI Exenatide -pharmacokinetics, pharmacodynamics, safety and tolerability in patients 75 years of age with Type 2 diabetes. Int J Clin Pharmacol Ther 2011; 49(2): 99-108.
59. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm198543.htm
60. Nauck M, Frid A, Hermansen K, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 2013; 15(3): 204-12
61. Vilsbøll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2007; 16(2): 231-7.
62. Zafon C, Creus C. A comparison on insulin regimen treatment of elderly (>70 years) and younger (<70 years) type 2 diabetic patients in actual clinical practice. Acta Diabetol 2011.
63. Sinclair AJ, Girling AJ, Bayer AJ. Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services. All Wales Research into Elderly (AWARE) Study. Diabetes Res Clin Pract 2000; 50(3): 203-12.
64. Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al. Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 2009; 32(2): 221-6.
65. Abbatecola AM, Paolisso G. Plasma glucose excursions in older persons with Type 2 diabetes mellitus. J Endocrinol Invest 2005; 28: 105-7.
66. Volpato S, Leveille SG, Blaum C, Fried LP, Guralnik JM. Risk factors for falls in older disabled women with diabetes: the Women’s Health and Aging Study. J Gerontol A Biol Sci Med Sci 2005; 60: 1539-45.